According to current knowledge, PTC is an umbrella term that encompasses several tumor types with mutually exclusive mutations, in most cases BRAF V600E, followed by RAS (15%) and chromosomal rearrangements leading to the expression of the kinase domains of BRAF or of receptor tyrosine kinases, such as RET, NTRK, and ALK (12%) [1]. This evidence concerns the gene BRAF and neoplasm.